Fatih Haslak

Dr. Fatih Haslak

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

3 January 2022 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
FHFatih Haslak
Fatih Haslak
AGAybuke Gunalp
Aybuke Gunalp
MCMemnune Nur Cebi
Memnune Nur Cebi
MYMehmet YILDIZ
Mehmet YILDIZ
AAAmra Adrovic Adrovic
Amra Adrovic Adrovic
OKOzgur Kasapcopur
Ozgur Kasapcopur
Objective: Considering the concerns regarding the coronavirus disease‐2019 (COVID‐19) vaccine safety among pediatric patients with inflammatory rheumatic diseases (IRD) due to a lack of data, an urgent need for studies evaluating safety profiles of vaccines emerged.Methods: Among participants vaccinated by CoronaVac inactive SARS‐CoV‐2 or BNT162b2 messenger RNA (mRNA) COVID‐19 (Pfizer‐BioNTech) vaccine, healthy children under 18 and patients under 21 with an at least 1‐year follow‐up period in our department for a childhood‐onset rheumatic disease were included into this cross‐sectional study.Results: Overall, 246 subjects (141 [57.3%] females) (biologic group: 43, non‐biologic group: 180, healthy control group: 23) were eligible for the study. The median age was 15.34 (12.02‐20.92) years. The most common adverse events were fatigue (n = 68, 27.6%), headache (n = 44, 17.9%), myalgia (n = 38, 15.4%), arthralgia (n = 38, 15.4%), and fever (n = 35, 14.2%). Only 3 subjects (2 patients with familial Mediterranean fever, and one healthy child) were considered to experienced serious adverse events, since they required hospitalization. Local reactions were seen in 20 (8.13%), and 27 patients (12.1%) had disease flares within 1 month after the vaccines. Although it was significantly higher in those who received the BNT162b2 mRNA vaccine (P < .001), there was no significant relationship between adverse event frequency and age, gender, the existing diseases, ongoing treatment regimens and pre‐vaccination COVID‐19 histories.Conclusion: Although immunogenicity studies for efficacy of the vaccines and long‐term follow‐up studies for adverse events monitoring are required, our study indicates an acceptable safety profile of COVID‐19 vaccines and encourages children with IRD to be vaccinated.

27 April 2020 in Balkan Medical Journal
Verified
Journal Article
Closed access
MYMehmet YILDIZ
Mehmet YILDIZ
FHFatih Haslak
Fatih Haslak
AAAmra Adrovic
Amra Adrovic
KBKenan Barut
Kenan Barut
OKOzgur Kasapcopur
Ozgur Kasapcopur
Autoinflammatory diseases are characterized by recurrent fever attacks and clinical findings that arise from impaired natural immunity and spread to a wide variety of organ systems. The concept of autoinflammatory disease emerged after the definition of familial Mediterranean fever (FMF) and Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS). Firstly, it is thought that this new group differs from the standard concept of autoimmune diseases, which is relatively better known in terms of basic features such as defects in innate immunity and the absence of antibodies. We have come a long way in understanding the genetic and pathogenetic mechanisms of this relatively new disease group in the past twenty years since they were first diagnosed. This growing understanding leads to some changes in the concept of autoinflammatory diseases. Recently, the definition of the autoinflammatory disease includes a wide range of diseases with different clinical features, mainly accompanied by changes in innate immune and rarely in humoral immunity. Owing to recent developments in molecular sciences and genetics, the spectrum of autoinflammatory diseases is rapidly expanding. In this review, clinical features, classification criteria, treatment options and long-term prognoses of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) syndrome, and other common autoinflammatory diseases are discussed in the light of current literature.

13 July 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
FHFatih Haslak
Fatih Haslak
MYMehmet YILDIZ
Mehmet YILDIZ
AAAmra Adrovic Adrovic
Amra Adrovic Adrovic
SSSezgin Sahin
Sezgin Sahin
OKOya Koker
Oya Koker
OKOzgur Kasapcopur
Ozgur Kasapcopur

5 June 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
FHFatih Haslak
Fatih Haslak
KBKenan Barut
Kenan Barut
CDCANSU DURAK
CANSU DURAK
AAAyten Aliyeva
Ayten Aliyeva
MYMehmet YILDIZ
Mehmet YILDIZ
OKOzgur Kasapcopur
Ozgur Kasapcopur

1 January 2022 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
MYMehmet YILDIZ
Mehmet YILDIZ
FHFatih Haslak
Fatih Haslak
AAAmra Adrovic Adrovic
Amra Adrovic Adrovic
IÜİpEk Ülkersoy
İpEk Ülkersoy
NGNeslihan Gücüyener
Neslihan Gücüyener
OKOzgur Kasapcopur
Ozgur Kasapcopur
Objective: The purpose of this study is to share our experience about clinical findings, natural course, and treatment response rates of a large cohort of patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome. Materials and Methods: Medical records of patients who were diagnosed with PFAPA syndrome between January 2010 and May 2021 at Istanbul University-Cerrahpasa Cerrahpasa Medical Faculty pediatric rheumatology department were reviewed retrospectively. Results: A total of 607 patients (females: 277, males: 330) with PFAPA syndrome were included. The median duration of episodes was 3 (1-15; interquartile range (IQR) 3-5) days, and the median interval between episodes was 20 days (5-120; IQR 15-30). The median age at the last attack and median disease duration were 66 (24-168; IQR 48-84) months and 40 (4-132; IQR 27.5-60) months, respectively. Fever (100%) was the most common clinical finding, followed by pharyngitis/exudative tonsillitis in 594 (97.9%), aphthous stomatitis in 308 (50.7%), cervical lymphadenopathy in 278 (45.8%), abdominal pain in 249 (41%), and arthralgia in 228 (37.6%) of the patients. Among the clinical findings, there was no statistical difference according to gender, except for cervical lymphadenitis being higher in males (P < .001). Of the patients who were given steroids during attacks, 94.6% were responsive. Colchicine was effective in 93 (63.7%) patients. The disease episodes ceased in 313 (95.4%) of patients who had tonsillectomy/adenoidectomy. Conclusions: Clinicians should be alert for additional symptoms such as abdominal pain, arthralgia, and headache apart from the cardinal signs. Although tonsillectomy is highly effective, its use is controversial. Colchicine may be a good alternative for prophylaxis. Cite this article as: Yıldız M, Haslak F, Adrovic A, et al. Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome: A single-center experience. Turk Arch Pediatr. 2022;57(1):46-52.